Biotechnology company Moderna Inc (Nasdaq:MRNA) and Catalent Inc (NYSE:CTLT), a provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, on Wednesday declared the expansion of a strategic collaboration to dedicate a new high-speed vial filling line for the manufacture of Moderna's COVID-19 vaccine at Catalent's biologics facility in Bloomington, Indiana.
The companies had announced in June 2020 that Catalent would provide aseptic vial filling and packaging from its Bloomington site, including additional staffing required for 24x7 manufacturing to support production of an initial 100 million doses of Moderna's vaccine. Moderna announced on 29 March 2021 that this milestone was achieved.
Under the newly expanded agreement, Catalent will now dedicate to Moderna's use a new high-speed filling line at the site through to June 2023.
This filling line can be used to manufacture the COVID-19 vaccine and potentially additional investigational programmes in Moderna's clinical pipeline. Catalent will also provide inspection, labelling, cartoning and final packaging for these programmes.
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Micron Biomedical names new scientific advisor to CEO
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences